NR1H4 and primary biliary cholangitis: For those with an incomplete response to UDCA, about 20–30 % of patients with PBC, obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, was officially approved in 2016, based on the result of successful phase 3 clinical trial [8].